← Patent-cliff monitor small molecule LEQVIO INCLISIRAN SODIUM
Loss of exclusivity August 2036 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name LEQVIO Active ingredient INCLISIRAN SODIUM Strength EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval December 2021 Marketing status RX
Listed patents Patent Expires Type 10851377 August 2036 use U-4249 10125369 August 2034 substance, product 12460206 August 2034 substance, product 8106022 December 2029 substance, product 10806791 December 2028 substance 9370582 December 2028 substance, product 8828956 December 2028 substance, product 10131907 August 2028 substance, product 8222222 December 2027 use U-4414 8809292 May 2027 substance, product
Regulatory exclusivity Code Expires ODE-555 February 2033 I-985 February 2029 NPP February 2029 NCE December 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.